Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.3500 +0.0400 (+12.90%)
Streaming Delayed Price Updated: 12:35 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about BNXT

< Previous 1 2 3 Next >
News headline image
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
Via ACCESS Newswire
News headline image
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
Via ACCESS Newswire
News headline image
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
Via ACCESS Newswire
News headline image
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
Via ACCESS Newswire
News headline image
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Via ACCESS Newswire
News headline image
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
Via ACCESS Newswire
News headline image
BioNxt Solutions Provides Bi-weekly MCTO Status Report
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
Via ACCESS Newswire
News headline image
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
Via ACCESS Newswire
News headline image
BioNxt Solutions Prepares for Human Bioequivalence Study For MS
Via ACCESS Newswire
News headline image
Clarification of Promotional Activities
Via ACCESS Newswire
News headline image
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
Via ACCESS Newswire
News headline image
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
Via ACCESS Newswire
News headline image
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
Via ACCESSWIRE
News headline image
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
Via ACCESSWIRE
News headline image
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
Via ACCESSWIRE
News headline image
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
Via ACCESSWIRE
News headline image
Terry Lynch Joins BioNxt as Capital Markets Advisor
Via ACCESSWIRE
News headline image
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
Via ACCESSWIRE
News headline image
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
Via ACCESSWIRE
News headline image
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
Via ACCESSWIRE
News headline image
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
Via ACCESSWIRE
News headline image
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
Via ACCESSWIRE
News headline image
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
Via ACCESSWIRE
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
BioNxt Reports Successful Results From ODF Cladribine PK Study
Via ACCESSWIRE
News headline image
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
Via ACCESSWIRE
News headline image
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.